Gene Editing and Virus Production Module
- Institution
- UT SOUTHWESTERN MEDICAL CENTER, TX
- Principal investigator
- Kevin Kyung Park
- Funding
- $211K
- Duration
- 2019–2029
Moonbase score
Still being scored
Abstract
Resource/Service Core: Gene Editing and Virus Production Module Abstract The Gene Editing and Virus Production (GEVP) Module will provide access to state-of-the-art genome editing technologies and generate DNA/RNA constructs for use in mammalian cultures/systems in vision research. This Module will also purify and concentrate both lentivirus and adeno-associated virus (AAV) for subsequent use in immortalized, primary cultures (maintained by individual investigators and the Stem Cell, Organoid and Cell Phenotyping Module) and in animals in vivo. The specific services provided within the GEVP Module are; 1) CRISPR guide-RNA to perform DNA editing or epigenetic modifications, 2) site-directed mutagenesis for generating point mutations, insertions, or deletion variants, 3) shRNA plasmid generation for knockdown/out experiments, 4) full sequencing of generated constructs, extensive documentation, and maintenance of DNA stocks for future use, 5) small to large scale endotoxin free plasmid purification for downstream applications, thorough confirmation of produced constructs at the transcript, protein, and subcellular level, consultation for optimal promoters and serotypes, and 6) generation of high-purity viruses for use in vitro or in vivo. Overall, the GEVP Module will provide access to leading-edge genome editing technologies, support a range of DNA/RNA and viral technologies, and provide the assistance and expertise required to test unique hypotheses posited by vision scientists at UTSW and neighboring institutions.
LOADING MOONBASE SCORE
Questions for UT SOUTHWESTERN MEDICAL CENTER
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · UT Southwestern Medical CenterNot yet scored
The role of novel lincRNAs in regulating RGC survival after injury
Kevin Kyung Park · $410K · 2024–2029
- NIH · UT Southwestern Medical Center61
Validation of Spinal Neurotensin Receptor 2 as an Analgesic Target
Amol M Patwardhan · $397K · 2020–2026
- NIH · UT Southwestern Medical Center58
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors
Ashish Ranjan · $504K · 2022–2028